Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy

Annals of Tropical Medicine and Parasitology

Volumn 100, Issue 3, 2006, Pages 223-227

  Dejenie Belay, A ^a   Asafa, Y ^b   Mesure, J ^a   Davidson, R N ^a,c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b Kafta Humera Hospital   (Ethiopia)

^c NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; MILTEFOSINE; NEVIRAPINE; STAVUDINE; STIBOGLUCONATE SODIUM; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ADULT; ANAMNESIS; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; RELAPSE; SKIN LEISHMANIASIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; DRUG COMBINATION; ORAL DRUG ADMINISTRATION;

NASO HEXACANTHUS;

ADMINISTRATION, ORAL; ADULT; ANTI-RETROVIRAL AGENTS; ANTIPROTOZOAL AGENTS; DRUG THERAPY, COMBINATION; HIV SEROPOSITIVITY; HUMANS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; TREATMENT OUTCOME;

EID: 33747851770     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: 10.1179/136485906X91440     Document Type: Article

References (16)

1. Bittencourt, A., Silva, N., Straatmann, A., Nunes, V. L., Follador, I. & Badaro, R. (2003). Post-kala azar dermal leishmaniasis associated with AIDS. Brazilian Journal of Infectious Diseases, 7, 229-233.
2. Collin, S., Davidson, R., Ritmeijer, K., Keus, K., Melaku, Y., Kipngetich, S. & Davies, C. (2004). Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clinical Infectious Diseases, 38, 612-619.
3. Delgado, J., Macias, J., Pineda, J. A., Corzo, J. E., Gonzalez-Moreno, M. P., de la Rosa, R., Sanchez-Quijano, A., Leal, M. & Lissen, E. (1999). High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. American Journal of Tropical Medicine and Hygiene, 61, 766-769.
4. Desjeux, P. & Alvar, J. (2003). Leishmania/HIV coinfections: epidemiology in Europe. Annals of Tropical Medicine and Parasitology, 97 (Suppl. 1), 3-15.
5. Gilad, J., Borer, A., Hallel-Halevy, D., Riesenberg, K., Alkan, M. & Schlaeffer, F. (2001). Post-kala azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection. Israeli Medical Association Journal, 3, 451-452.
6. Khalil, E. A., Nur, N. M., Zijlstra, E. E., El-Hassan, A. M. & Davidson, R. N. (1996). Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala azar dermal leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 90, 187-188.
7. Lyons, S., Veeken, H. & Long, J. (2003). Visceral leishmaniasis and HIV in Tigray, Ethiopia. Tropical Medicine and International Health, 8, 733-739.
8. Ridolfo, A. L., Gervasoni, C., Antinori, S., Pizzuto, M., Santambrogio, S., Trabattoni, D., Clerici, M. & Galli, M. (2000). Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapyin an AIDS patient infected with Leishmania infantum. Journal of Infection, 40, 199-202.
9. Rios-Buceta, L., Buezo, G. F., Penas, P. F., Dauden-Tello, E., Aragues-Montanes, M., Fraga-Fernandez, J. & Garcia-Diez, A. (1996). Post-kala-azar dermal leishmaniasis in an HIV-patient. International Journal of Dermatology, 35, 303-304.
10. Ritmeijer, K., Veeken, H., Melaku, Y., Leal, G., Amsalu, R., Seaman, J. & Davidson, R. N. (2001). Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV coinfected patients have a poor outcome. Transactions of the Royal Society of Tropical Medicine and Hygiene, 95, 668-672.
11. Schraner, C., Hasse, B., Hasse, U., Baumann, D., Faeh, A., Burg, G., Grimm, F., Mathis, A., Weber, R. & Gunthard, H. F. (2005). Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1. Clinical Infectious Diseases, 40, e120-e124.
12. Sindermann, H., Engel, K. R., Fischer, C. & Bommer, W. (2004). Miltefosine Compassionate Use Program. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clinical Infectious Diseases, 39, 1520-1523.
13. Soto, J., Arana, B. A., Toledo, J., Rizzo, N., Vega, J. C., Diaz, A., Luz, M., Gutierrez, P., Arboleda, M., Berman, J. D., Junge, K., Engel, J. & Sindermann, H. (2004). Miltefosine for New World cutaneous leishmaniasis. Clinical Infectious Diseases, 38, 1266-1272.
14. Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A. & Berman, J. (2002). Oral miltefosine for Indian visceral leishmaniasis. New England Journal of Medicine, 347, 1739-1746.
15. World Health Organization (1996). Manual on Visceral Leishmaniasis Control. Document WHO/LEISH/96/ 40. Geneva: WHO.
16. Zijlstra, E. E., Musa, A. M., Khalil, E. A., El-Hassan, I. M. & El-Hassan, A. M. (2003). Post-kala-azar dermal leishmaniasis. Lancet Infectious Diseases, 3, 87-98.